Skip to main content

Table 1 Baseline characteristics of migraine patients who received either zinc supplement or placebo

From: Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial

Variables Zinc groupa Placebo groupb t df P-value*
Age (year) 37.40 ± 12.26 38.87 ± 13.69 −0.50 78.0 0.61
Gender (female) (%) 82.5 70.0 1.72 1 0.18
Education (university graduated) (%) 32.5 25.0 0.54 1 0.45
Weight (kg) 62.58 ± 12.48 66.00 ± 15.14 −1.10 78 0.27
BMI (kg/m2) 24.36 ± 4.19 25.50 ± 4.91 − 1.11 78 0.26
Zinc (μg/dL) 85.41 ± 12.87 84.20 ± 11.65 0.44 78 0.66
Characteristics of migraine attacks
 Headache severityc 7.22 ± 1.14 6.80 ± 0.93 1.81 78 0.07
 Attacks frequency (per month) 8.80 ± 6.16 9.45 ± 5.39 −0.50 78 0.61
 Attacks duration (hour) 17.67 ± 13.59 22.85 ± 16.47 −1.53 78 0.13
 HDRd 151.67 ± 138.87 198.00 ± 138.98 −1.49 78 0.14
  1. Abbreviation: BMI body mass index, HDR headache diary result, VAS visual analog scale
  2. All values are presented as mean (SD) or percent
  3. aReceived zinc capsule containing 220 mg zinc sulfate one time per day
  4. bReceived placebo capsule containing lactose one time per day
  5. cMeasured by VAS that ranked headache severity from 1 to 10
  6. dDetermined by formula: frequency × duration
  7. *Obtained from independent sample t-test or Chi-square test, as appropriate